Inflammatory arthritis: An overview for primary care physicians

Postgraduate Medicine

Volumn 121, Issue 2, 2009, Pages 148-162

  Brent, Lawrence H ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

Ankylosing spondylitis; Inflammatory arthritis; Psoriatic arthritis; Rheumatoid arthritis; Treatment

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT;

ANKYLOSING SPONDYLITIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG MEGADOSE; GENERAL PRACTITIONER; HUMAN; MEDICAL SPECIALIST; PATIENT REFERRAL; PRIMARY MEDICAL CARE; PSORIATIC ARTHRITIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ARTHRITIS; PATIENT CARE; PRIMARY HEALTH CARE;

ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CONTINUITY OF PATIENT CARE; HUMANS; PRIMARY HEALTH CARE; REFERRAL AND CONSULTATION; SPONDYLITIS, ANKYLOSING;

EID: 64849112200     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.03.1987     Document Type: Review

References (139)

1. Bergman MJ. Social and economic impact of inflammatory arthritis. Postgrad Med. 2006; Spec No:5-11.
2. US Department of Health and Human Services and the Centers for Disease Control and Prevention Coordinating Center for Health Promotion. Targeting arthritis. Reducing disability for 43 million Americans 2005. Atlanta, GA: CDC; 2005.
3. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130-136. (Pubitemid 40488741)
4. Minaur NJ, Jacoby RK, Cosh JA, Taylor G, Rasker JJ. Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol. 2004;69(suppl):3-8. (Pubitemid 38327484)
5. Eberhardt K, Larsson BM, Nived K, Lindqvist E. Work disability in rheumatoid arthritis - development over 15 years and evaluation of predictive factors over time. J Rheumatol. 2007;34(3):481-487. (Pubitemid 46364001)
6. Geuskens GA, Burdorf A, Hazes JM. Consequences of rheumatoid arthritis for performance of social roles - a literature review. J Rheumatol. 2007;34(6):1248-1260. (Pubitemid 46898105)
7. Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B. Disease activity score - 28 values differ considerably depending on patient's pain perception and sex. J Rheumatol. 2007;34(12):2382-2387. (Pubitemid 350230659)
8. Dellhag B, Bjelle A. A five-year followup of hand function and activities of daily living in rheumatoid arthritis patients. Arthritis Care Res. 1999;12(1):33-41. (Pubitemid 29507595)
9. Odegård S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. Scand J Rheumatol. 2005;34(6):441-447. (Pubitemid 43062198)
10. Odegård S, Finset A, Mowinckel P, Kvien TK, Uhlig T. Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis. Ann Rheum Dis. 2007;66(9):1195-1201. (Pubitemid 47309737)
11. Feldman DE, Bernatsky S, Haggerty J, et al. Delay in consultation with specialists for persons with suspected new-onset rheumatoid arthritis: a population-based study. Arthritis Rheum. 2007;57(8):1419-1425. (Pubitemid 350308839)
12. Harrison MJ, Tricker KJ, Davies L, et al. The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. J Rheumatol. 2005;32(12):2330-2336. (Pubitemid 41782233)
13. Jacobi CE, Mol GD, Boshuizen HC, Rupp I, Dinant HJ, Van Den Bos GA. Impact of socioeconomic stants on the course of rheumatoid arthritis and on related use of health care services. Arthritis Rheum. 2003;49(4):567-573. (Pubitemid 36988312)
14. Marra CA, Lynd LD, Esdaile JM, Kopec I, Anis AH. The impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environment. Rheumatology(Oxford). 2004;43(11):1390-1397. (Pubitemid 39480926)
15. Groessl EJ, Ganiats TG, Sarkin AJ. Sociodemographic differences in quality of life in rheumatoid arthritis. Pharmacoeconomics. 2006;24(2):109-121. (Pubitemid 43242194)
16. Maiden N, Capell HA, Madhok R, Hampson R, Thomson EA. Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients? Ann Rheum Dis. 1999;58(9):525-529. (Pubitemid 29409097)
17. Allaire S, Wolfe F, Niu J, La Valley MP. Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum. 2008;59(4):474-480.
18. Mikuls TR. Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2003;17(5):729-752. (Pubitemid 37038178)
19. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum. 2005;35(1):8-17. (Pubitemid 41111466)
20. Snow MH, Mikuls TR. Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol. 2005;17(3):234-241. (Pubitemid 40616568)
21. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50(6):1740-1751. (Pubitemid 38725085)
22. Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol. 2004;16(3):254-261. (Pubitemid 38530494)
23. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis. 2007;66(3):308-312. (Pubitemid 46579629)
24. Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry. 2007;29(2):147-155. (Pubitemid 46320681)
25. Bazzichi L, Maser J, Piccinni A, et al. Quality of life in rheumatoid arthritis: impact of disability and lifetime depressive spectrum symptomatology. Clin Exp Rheumatol. 2005;23(6):783-788. (Pubitemid 43040505)
26. Kosinski M, Kujawski SC, Martin R, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care, 2002;8(3):231-240. (Pubitemid 34256633)
27. West E, Jonsson SW. Health-related quality of life in rheumatoid arthritis in Northern Sweden: a comparison between patients with early RA, patients with medium-term disease and controls, using SF-36. Clin Rheumatol. 2005;24(2):117-122. (Pubitemid 40552962)
28. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61(suppl 3):iii8-iii10.
29. Kataria RK, Brent LH. Spondyloarthropathies. Am Fam Physician. 2004;69(12):2853-2860.
30. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatologieal database. German Collaborative Arthritis Centers. J Rheumatol. 2000;27(3):613-622. (Pubitemid 30151336)
31. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4-11. (Pubitemid 44360187)
32. Dagfinrud H, Kjeken I, Mowinckel P, Hagen KB, Kvien TK. Impact of functional impairment in ankylosing spondylitis: impairment, activity limitation. and participation restrictions. J Rheumatol. 2005;32(3):516-523. (Pubitemid 40381425)
33. Zink A, Thiele K, Huscher D, et al. Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2006;33(1):86-90. (Pubitemid 43054286)
34. Song IH, Sieper J, Rudwaleit M. Diagnosing early ankylosing spondylitis. Curr Rheumatol Rep. 2007;9(5):367-374. (Pubitemid 47597055)
35. Dagfinrud H, Vollestad NK, Loge JH, Kvien TK, Mengshoel AM. Fatigue in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum. 2005;53(1):5-11. (Pubitemid 40216345)
36. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33(11):2167-2172. (Pubitemid 44749774)
37. Ward MM, Reveille JD, Learch TJ, Davis JC Jr, Weisman MH. Impact of ankylosing spondylitis on work and family life: comparisons with the US population. Arthritis Rheum. 2008;59(4):497-503.
38. Mau W, Listing J, Huscher D, Zeidler H, Zink A. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol. 2005;32(4):721-728. (Pubitemid 40524707)
39. Ozgul A, Peker F, Taskaynatan MA, et al. Effect of ankylosing spondylitis on health-related quality of life and different aspects of social life in young patients. Clin Rheumatol. 2006;25(2):168-174. (Pubitemid 43372313)
40. Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol. 2006;24(5):438-447. (Pubitemid 44332869)
41. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(suppl 2):ii14-ii17. (Pubitemid 40288513)
42. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-835. (Pubitemid 44556851)
43. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321-328. (Pubitemid 44777680)
44. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol. 2001;28(8):1842-1846. (Pubitemid 32726931)
45. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9(2):140-147. (Pubitemid 38457272)
46. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280-284.
47. van der Heijde DM, van 't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49(11):916-920. (Pubitemid 20360757)
48. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42(2):244-257. (Pubitemid 36305610)
49. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796-R806.
50. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid armritis. Arthritis Rheum. 1995;38(6):727-735.
51. Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum. 1998;41(9):1564-1570. (Pubitemid 28459914)
52. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria (or rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34-40.
53. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(5 suppl 39):S93-S99. (Pubitemid 46657516)
54. Makinen H, Hannonen P, Sokka T. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin Exper Rheumatol. 2006;24(6 suppl 43):S22-S28. (Pubitemid 44696864)
55. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 1981;24(10):1308-1315. (Pubitemid 11022943)
56. Prevoo ML, van Gestel AM, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol. 1996;35(11):1101-1105.
57. van Riel PL, van Gestel AM. Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis. 2000;59(suppl 1):i28-i31.
58. McQueen FM, Ostergaard M. Established rheumatoid arthritis - new imaging modalities. Best Pract Res Clin Rheumatol. 2007;21(5):841-856. (Pubitemid 47381242)
59. Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M, Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford). 1999;38(9):878-882. (Pubitemid 29507371)
60. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21(12):2281-2285.
61. Zochling J, Braun J. Remission in ankylosing spondylitis. Clin Exp Rheumatol. 2006;24(6 suppl 43):S88-S92. (Pubitemid 44696874)
62. Baraliakos X, Brandt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum. 2005;53(6):856-863. (Pubitemid 41811126)
63. Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7(3):R439-R444. (Pubitemid 40775172)
64. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48(6):1667-1675. (Pubitemid 36682375)
65. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford). 2005;44(3):342-348. (Pubitemid 40361291)
66. Braun J, Sieper J, Bollow M. Imaging of sacroiliitis. Clin Rheumatol. 2000;19(1):51-57. (Pubitemid 30123242)
67. Oostveen J, Prevo R, den Boer J, van de Laar M. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol. 1999;26(9):1953-1958. (Pubitemid 30007064)
68. Kavanaugh A, Cassell S. The assessment of disease activity and outcomes in psoriatic arthritis. Clin Exp Rheumatol. 2005;23(5 suppl 39):S142-S147. (Pubitemid 46657520)
69. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum. 2004;50(1):24-35. (Pubitemid 38084284)
70. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesilis in ankylosing spondylitis. Ann Rheum Dis. 2003;62(2):127-132.
71. Taylor WJ. Assessment of outcome in psoriatic arthritis. Curr Opin Rheumatol. 2004;16(4):350-356. (Pubitemid 38803134)
72. Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007;57(4):581-587. (Pubitemid 47384917)
73. Kavanaugh A, Fransen J. Defining remission in psoriatic arthritis. Clin Exp Rheumatol. 2006;24(6 suppl 43):S83-S87. (Pubitemid 44696873)
74. Smolen JS, Aletaha D. What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol. 2006;24(6 suppl 43):S7-S13. (Pubitemid 44696862)
75. Keystone EC. Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists an opportunity to improve outcomes. Nat Clin Pract Rheumatol. 2006;2(11):594-601. (Pubitemid 44650947)
76. Smolen JS, Aletaha D, Machold KP. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2005;19(1):163-177. (Pubitemid 40003947)
77. Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum. 2005;52(4):1009-1019. (Pubitemid 40530106)
78. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37. (Pubitemid 43122183)
79. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675-681. (Pubitemid 38296553)
80. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432-3443. (Pubitemid 39488667)
81. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003:349(20):1907-1915. (Pubitemid 37409707)
82. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865-876. (Pubitemid 46768126)
83. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(8):2263-2271. (Pubitemid 41117408)
84. Emery P, Fleischmann R,Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390-1400.
85. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-2806. (Pubitemid 44497758)
86. Keystone EC, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis. Published online. April 3, 2008.
87. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162-1167. (Pubitemid 47309731)
88. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-997.
89. Nagle M. Amgen expounds IL-17 potential as arthritis target. http://www.drugresearcher.com/news/ng.asp?n=79206-amgen-wyeth-inflammation-il- arthritis. Accessed May 16, 2008.
90. Geboes L, Dumoutier L, Kelchtermans H, et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum. 2009;60(2):390-395.
91. Stanczyk J, Ospell C, Gay S. Is there a future for small molecule drugs in the treatment of rheumatic diseases? Curr Opin Rheumatol. 2008;20(3):257-262.
92. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903- 911. (Pubitemid 32900579)
93. van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol. 1995;22(9):1792-1796.
94. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001;111(6):446-451. (Pubitemid 33016415)
95. Han C, Smolen J, Kavanaugh A, St Clair EW, Baker D, Bala M. Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. Arthritis Rheum. 2008;59(4):510-514.
96. Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2006;20(5):849-863. (Pubitemid 44382383)
97. Möttönen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease- modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 2002;46(4):894-898. (Pubitemid 34303799)
98. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann, M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43(7):906-914. (Pubitemid 38996967)
99. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of light control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263-269. (Pubitemid 38942816)
100. Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999;353(9164):1568-1573. (Pubitemid 29219206)
101. Leirisalo-Repo M, Kautiainen H, Laasonen L, et al. A randomized, double-blind, placebo-controlled study on addition of infliximab to the FIN-RACO DMARD combination therapy for initial six months in patients with early active rheumatoid arthritis. The NEO-RACO study [abstract OP-0009]. Ann Rheum Dis. 2008;67( suppl II):50.
102. Smolen JS, van der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006;54(3):702-710.
103. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381-3390. (Pubitemid 41612204)
104. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis. 2008;67(2):266-269.
105. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol. 2006;33(7):1422-1430. (Pubitemid 44025163)
106. Kahn KL, MacLean CH, Liu H, et al. The complexity of care for patients with rheumatoid arthritis: metrics for better understanding chronic disease care. Med Care. 2007;45(1):55-65.
107. Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum. 2005;53(2):241-248. (Pubitemid 40530165)
108. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH. Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis. 2002;61(4):290-297. (Pubitemid 34257737)
109. Feldfkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs positive patients with ankylosing spondylitis. Rheumatol Int. 2003;23(2):61-66. (Pubitemid 36384722)
110. Zochling J, Braun J. Quality indicators, guidelines and outcome measures in ankylosing spondylitis. Clin Exp Rheumatol. 2007;25(6 suppl 47):147-152. (Pubitemid 350167900)
111. Sieper J, Rudwaleit M. Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis. 2005;64(5):659-663. (Pubitemid 40559289)
112. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group, Classification criteria for psoriatic arthritis: development ofnew criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-2673. (Pubitemid 44205029)
113. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford). 2004;43(2):143-147. (Pubitemid 38219666)
114. Trexall [package insert]. Pamona, NY: Barr Laboratories, Inc; 2005.
115. Strangfeld A, Listing J. Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol. 2006;20(6):1181-1195.
116. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692-701.
117. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56(5):1433-1439. (Pubitemid 46764070)
118. Mayo Clinic Staff. Non-Hodgkin's lymphoma. Mayo Foundation for Medical Education and Research. http://www.mayoclinic.com/healthmon-hodgkins-lymphonia/ DS00350/DSECTION=symptoms. Accessed February 3, 2009.
119. Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52(2):412-420. (Pubitemid 40216304)
120. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004;116(5):305-311. (Pubitemid 38230289)
121. Humira (adalimumab) [package insert]. North Chicago, IL: Abbott Laboratories; 2007.
122. Remicade (infliximab) [package insert]. Malvern, PA: Centocor, Inc; 2007.
123. Enbrel (etanercept) [package insert]. Thousand Oaks, CA: Immunex Corporation, marketed by Amgen and Wyeth Pharmaceuticals; 2008.
124. Orencia (abatacept) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2007.
125. Rituxan (rituximab) [package insert]. San Francisco, CA: Genentech, Inc; 2008.
126. Feinstein DE, Brent LH. The complexity of the differential diagnosis for the inflammatory arthritides. Postgrad Med. 2006; Spec No:12-23.
127. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379- 1390. (Pubitemid 46590387)
128. Peschken CA, Esdaile JM. Rheumatic diseases in North America's indigenous peoples. Semin Arthritis Rheum. 1999;28(6):368-391. (Pubitemid 29289375)
129. Walsh B, Yocum DE, Khan MA. Arthritis and HLA-B27 in native North American tribes. Curr Opin Rheumatol. 1998;10(4):319-325. (Pubitemid 28421245)
130. Brockbank J, Gladman D. Diagnosis and management of psoriatic arthritis. Drugs. 2002;62(17):2447-2457. (Pubitemid 35448135)
131. Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968;37(147):393-406.
132. Prevoo ML. van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-48.
133. Fransen J, van Riel PL. DAS remission cut points. Clin Exp Rheumatol. 2006;24(6 suppl 43):S29-S32. (Pubitemid 44710278)
134. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41(10):1845-1850. (Pubitemid 28465539)
135. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44(8):1876-1886. (Pubitemid 32758236)
136. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis. 2004;63(11):1438-1444. (Pubitemid 39433948)
137. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244. (Pubitemid 8387357)
138. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66(11):1443-1449. (Pubitemid 350032650)
139. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMLT): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375-382.